Vericel Corporation research snapshot
VCEL AI stock analysis currently reads Vericel as a commercial-stage regenerative medicine company with two FDA-approved cell therapy products MACI and Epicel, strong recent revenue growth of about 30% year over year in Q1 2026, a recently profitable TTM earnings profile, and a balance sheet with $145 million in cash and modest debt. The July 10, 2026 setup is constructive but not without caveats. Vericel trades at a premium valuation reflecting the growth and margin expansion expectations already embedded in the stock. The VCEL AI stock forecast uses scenario ranges rather than a fixed target, while the VCEL AI technical analysis shows the share price above both its 50-day and 200-day moving averages with positive momentum. This page is informational research, not investment advice.
Current price
$47.00 close on July 10, 2026
Market cap
$2.40 billion calculated from $47.00 x 51.07 million shares
AI score
53 / 100
Rating
Specialized regenerative medicine company with FDA-approved cell therapies, strong revenue growth, improving profitability trajectory, offset by narrow product concentration, high valuation multiple, and small-cap liquidity risk
Trend status
Bullish, above both the 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Vericel develops and commercializes cell therapies for sports medicine and severe burn care. Its approved products MACI, Epicel, and NexoBrid serve defined patient populations with meaningful unmet needs. | Medium-high |
| Moat | Vericel has FDA-approved cell therapy manufacturing processes that are complex, regulated, and difficult to replicate. The autologous nature of MACI and Epicel creates a biological switching cost, though reimbursement dynamics and competition from alternative knee treatments limit pricing power. | Medium |
| Management | CEO Dominick Colangelo has led Vericel since 2024, succeeding long-time CEO Nick Colangelo. Recent insider selling by executives including Sean Flynn and Jonathan Hopper is worth monitoring, though some sales may reflect normal portfolio diversification. | Medium |
| Financial trend | TTM revenue of $292 million with 30% Q1 2026 year-over-year growth. Net income of $21 million on a TTM basis after years of losses. Balance sheet shows $145 million cash and modest debt with a current ratio of 5.18x. | Medium-high |
| Valuation | At the July 10 close of $47.00, reported market data showed roughly 111.9x trailing P/E, 6.70x price to book, 8.69x price to sales, and 56.6x price to free cash flow. The premium reflects above-market expected earnings growth of 71% in the coming year. | Medium |
| Technical trend | VCEL was above its 50-day moving average near $32.82 and well above its 200-day moving average. The stock is near its 52-week high of $48.33, reflecting a strong upward trend over the past six months. | Medium |
| Risk level | Key risks include narrow product concentration on MACI and Epicel, managed care reimbursement changes, pipeline execution, manufacturing and regulatory compliance, insider selling, small-cap volatility, and a high short interest of about 10.4% of float. | High |
| AI confidence | The audited financial and operating record is well documented, but a model cannot reliably predict biotech reimbursement decisions, surgical volume trends, pipeline outcomes, or market sentiment changes that drive VCEL share price. | High data confidence |
| Investment certainty | The current price embeds a high-growth expectation. A margin of safety would require conviction that MACI and Epicel revenue growth continues at a high rate and that operating leverage drives meaningful margin expansion over several years. | Medium-low |
VCEL AI stock forecast
The VCEL AI stock forecast is scenario-based. A reproducible three-year model using the July 10 price, $0.42 TTM EPS, 50%, 25%, and 5% EPS growth assumptions, and 80x, 60x, and 35x terminal P/E assumptions produces mechanical values near $113, $49, and $17. Those outputs are sensitivity cases, not price targets, because Vericel earnings depend on MACI procedure volumes, Epicel and NexoBrid adoption, operating margin expansion, payer reimbursement, pipeline development, and competitive dynamics.
$80 to $115 before considering dilution
More likely if MACI knee procedure volumes grow above expectations, Epicel and NexoBrid burn care revenue accelerates, operating margins expand faster than currently projected, pipeline programs show clinical progress, and the market re-rates VCEL at a premium consistent with sustained high growth.
$40 to $55
More likely if MACI growth moderates to mid-teens percentage, burn care revenue grows steadily, operating margins improve gradually toward mid-teens percentage, payer coverage remains stable, and the stock holds its current valuation multiple near a forward P/E of about 60-70x forward earnings.
$20 to $35
More likely if MACI volume growth disappoints, payer reimbursement tightens, a competitor introduces a viable alternative, Epicel procedure volumes decline, operating losses recur, management execution slips, or the broader small-cap biotech sector experiences a valuation reset.
VCEL AI technical analysis
VCEL AI technical analysis is bullish as of the July 13, 2026 data cutoff. The stock closed at $47.00 on July 10, above both its 50-day moving average of $32.82 and its 200-day moving average. The stock has rallied from its 52-week low of $28.95 and is testing its 52-week high of $48.33, suggesting strong intermediate-term momentum.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $47.00 | MarketBeat listed the July 10, 2026 regular-session close at $47.00. |
| Immediate support | $42.00 to $44.00 | This zone marks the early-June consolidation area and provides a first pullback reference. |
| Deeper support | $35.00 to $38.00 | This range brackets the June 2026 breakout level and the rising 50-day moving average area. |
| Near resistance | $48.00 to $49.00 | The 52-week high of $48.33 is the immediate resistance zone. A breakout above this level would open the path to higher prices. |
| Upper resistance | $55.00 to $57.00 | This zone corresponds to the average analyst price target of $52.50 and the upper end of recent analyst estimates near $64. |
| Moving averages | 50-day $32.82, 200-day at significant discount | Price well above both averages confirms a strong uptrend. The wide gap between price and the 50-day could mean a mean-reversion pullback is possible. |
| Momentum | Strong positive, near overbought | VCEL has rallied from $36 at the start of 2026 to $47, a gain of about 30% year to date. Momentum is strong but extended in the near term. |
| Volume | Average daily volume ~674,000 shares | Volume has been above average on up days recently, which supports the bullish trend. The 10.4% short interest ratio indicates potential for short squeezes. |
| Volatility | Watch earnings around July 30, 2026 | Next quarterly results and guidance are the most imminent catalyst. Biotech stocks are known for sharp post-earnings moves. |
| Invalidation | Close below $42.00, then below $35.00 | A sustained break below the $42 support weakens the short-term bullish setup. A close below $35 would challenge the intermediate-term trend. |
VCEL AI trading strategy
The VCEL AI trading strategy below is a rules-based research framework, not personal advice. It links price levels with Vericel revenue growth, MACI procedure volume, Epicel and NexoBrid adoption, operating margins, cash position, pipeline catalysts, and industry sector flows.
Watch for VCEL to hold above $44 and challenge the $48 to $49 resistance zone with increasing volume and positive catalysts from quarterly earnings or MACI procedure volume updates.
A failed breakout at resistance followed by a close below $44 should reduce trend confidence, particularly if revenue growth slows or margins disappoint.
If VCEL retests the $35 to $38 zone, evaluate whether the pullback is driven by sector-wide selling rather than company-specific deterioration. Compare the pullback price with normalized earnings power, cash per share, and the long-term procedure volume opportunity.
Do not treat a price decline as automatically attractive if it coincides with weaker MACI growth, a payer coverage setback, management guidance reduction, or a broader biotech valuation compression.
Track quarterly MACI and Epicel revenue, procedure volume reports, gross margin trends, operating expense leverage, cash position, pipeline milestones, payer coverage decisions, insider trading patterns, and short interest changes.
Position sizing should reflect that VCEL combines product concentration risk, biotech sector volatility, small-cap liquidity risk, and a premium valuation. It is not a diversified holding or a precise AI price prediction.
Investment research summary
Customers, primarily orthopedic surgeons and burn centers, pay Vericel for autologous cell therapies that repair knee cartilage and provide permanent skin replacement for severe burns. Vericel turns a complex, FDA-regulated cell manufacturing process into revenue that grows as procedure volumes expand and new products gain adoption.
Vericel operates FDA-approved cell therapy manufacturing facilities with regulated autologous processing that is difficult to replicate. MACI and Epicel have established clinical track records and specialist adoption. The moat is meaningful operationally, but Vericel faces risk from alternative knee treatments, evolving coverage policies, and potential competition.
The thesis fails if MACI procedure volume growth slows, payer coverage tightens, a competitor introduces a superior knee cartilage repair option, Epicel adoption plateaus, manufacturing costs rise, operating margins fail to expand, the product pipeline stalls, cash burns down, or the premium valuation compresses.
Management is executing a commercial growth strategy centered on MACI market penetration, Epicel adoption, and NexoBrid expansion under CEO Dominick Colangelo. Insider sales by senior executives in 2026 are a factor to monitor, though they may not signal a loss of confidence. Capital allocation priorities include organic growth investment and maintaining a cash-rich balance sheet.
Regenerative medicine and cell therapy represent a long-term growth area in healthcare, supported by an aging population, active lifestyles driving sports injuries, and continued medical innovation. The counterweight is a challenging reimbursement environment, regulatory complexity, and the high cost of cell therapy manufacturing.
The July 10 price of $47.00 reflects a premium valuation with a trailing P/E over 100x, pricing in several years of strong growth and margin expansion. A margin of safety is limited unless the company delivers sustained high revenue growth and operating leverage that brings the forward multiple down over time.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VCEL quote reference | $47.00 regular-session close on July 10, 2026 | MarketBeat VCEL overview | July 13, 2026 |
| Market capitalization | $2.40 billion calculated from $47.00 x 51.07 million shares. Yahoo Finance reported $2.361 billion intraday, reflecting intraday price variation. | MarketBeat VCEL statistics and Yahoo Finance VCEL summary | July 13, 2026 |
| Share count | Approximately 51.07 million shares outstanding as of most recent filings | MarketBeat VCEL statistics | July 13, 2026 |
| TTM revenue and net income | TTM revenue approximately $292 million with TTM net income of approximately $21.5 million. Fiscal 2025 revenue was $276 million with net income of $16.5 million. | Yahoo Finance VCEL financials and TradingView fundamentals | July 13, 2026 |
| Q1 2026 quarterly results | Revenue of $68.42 million, up 30.1% year over year, beating the $63.68 million estimate. GAAP EPS of -$0.12, beating the -$0.15 estimate. Net loss of $6.3 million for the quarter. | MarketBeat VCEL earnings and GlobeNewswire earnings release | July 13, 2026 |
| Cash, no debt, and balance sheet | $145.34 million total cash, $485.63 million total assets, $129.40 million total liabilities at Q1 2026. Current ratio of 5.18x and low debt-to-equity of 26.68%. | Yahoo Finance VCEL key statistics and TradingView balance sheet | July 13, 2026 |
| TTM valuation inputs | Reported 111.9x trailing P/E, 95.9x forward P/E, 6.70x P/B, 8.69x P/S, and 56.6x P/FCF. Verified inputs are $0.42 EPS, $7.01 book value per share, and $0.83 FCF per share. | MarketBeat VCEL statistics and Pineify financial_rigor.py | July 13, 2026 |
| Technical data | 50-day moving average $32.82, 200-day moving average at a significant discount, 52-week range $28.95 to $48.33, average volume 674,000 shares, and short interest of 10.41% of float. | MarketBeat VCEL statistics and TradingView VCEL overview | July 13, 2026 |
| Analyst consensus | Consensus rating of Hold (2.43 out of 4) with average price target of $52.50, ranging from $42 low to $64 high. Earnings expected to grow 71% in the coming year. | MarketBeat VCEL analyst forecast | July 13, 2026 |
This VCEL AI stock analysis is an informational research tool only. It is not investment advice, a recommendation to buy or sell Vericel stock, or a guarantee of future returns. Forecast scenarios are based on available data as of July 13, 2026, can be wrong, and should be updated when quarterly earnings, product revenue reports, payer coverage updates, pipeline milestones, management changes, or sector valuation conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
